Department of Organ Transplant Medicine, Graduate School of Medicine, Tokyo Women's Medical University, Japan; Department of Nephrology, Graduate School of Medicine, Tokyo Women's Medical University, Japan; Department of Urology, Yochomachi Clinic, Tokyo, Japan.
Department of Organ Transplantation and General Surgery, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan.
Vaccine. 2024 Oct 3;42(23):126221. doi: 10.1016/j.vaccine.2024.126221. Epub 2024 Aug 24.
Poor post-vaccination production of antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a concern among solid organ transplant (SOT) recipients. Furthermore, the timing and kinetics of antibody titers after the second vaccine dose are unknown. We conducted a multicenter prospective observational study that included 614 SOT recipients: 460 kidney, 53 heart, 50 liver, 20 lung, and 31 simultaneous pancreas-kidney (SPK). The participants received two doses of the mRNA vaccine (Pfizer BNT162b2 or Moderna mRNA-1273), as indicated. Serum samples were collected before the first and second vaccinations and at 1, 3, and 6 months after the second vaccine dose, which were then assessed for SARS-CoV-2 antibodies. The overall seropositivity rate was 43% at 1 month after administration of the second vaccine dose; it gradually increased to 68% at 3 months after second dose administration and to 70% at 6 months. In addition, recipient of kidney, lung or SPK transplants had lower antibody titers at the 3- and 6-month time points than did the other recipients. SOT recipients acquired SARS-CoV-2 S-IgG antibodies slowly, and the peak titer differed significantly from that of the general population.
在实体器官移植（SOT）受者中，接种疫苗后针对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的抗体产生不佳令人担忧。此外，第二剂疫苗后抗体滴度的出现时间和动力学尚不清楚。我们进行了一项多中心前瞻性观察研究，共纳入 614 名 SOT 受者：460 例肾脏、53 例心脏、50 例肝脏、20 例肺和 31 例胰肾联合（SPK）。受者按照指示接受了两剂 mRNA 疫苗（辉瑞 BNT162b2 或 Moderna mRNA-1273）。在第一剂和第二剂疫苗接种前以及第二剂疫苗接种后 1、3 和 6 个月收集血清样本，然后评估 SARS-CoV-2 抗体。第二剂疫苗接种后 1 个月的总体血清阳性率为 43%；逐渐增加至第二剂疫苗接种后 3 个月的 68%和 6 个月的 70%。此外，与其他受者相比，肾脏、肺或 SPK 移植受者在 3 个月和 6 个月时的抗体滴度较低。SOT 受者获得 SARS-CoV-2 S-IgG 抗体的速度较慢，峰值滴度与一般人群有显著差异。
